Neurology drug pipeline

CNS therapeutics — neurodegeneration, demyelinating disease, epilepsy, migraine, ALS, rare neurological conditions.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. GlaxoSmithKline · 21 drugs
2. Massachusetts General Hospital · 16 drugs
3. Biogen · 13 drugs
4. Mario Negri Institute for Pharmacological Research · 11 drugs
5. UCB Pharma · 11 drugs
6. Seoul National University Hospital · 11 drugs
7. Merck Sharp & Dohme LLC · 10 drugs
8. Assistance Publique - Hôpitaux de Paris · 10 drugs
9. Eisai Inc. · 10 drugs
10. Allergan · 10 drugs

Key drug classes

• Benzodiazepine · 30
• Botulinum toxin · 30
• Atypical antipsychotic · 23
• Selective serotonin reuptake inhibitor (SSRI) · 20
• Dopamine agonist · 19
• Cholinesterase inhibitor · 17
• Sympathomimetic amine; CNS stimulant · 17
• Anticonvulsant / Mood stabilizer · 14
• NMDA receptor antagonist · 13
• Anticonvulsant / Antiepileptic agent · 13
• Botulinum toxin type A · 13
• Melatonin receptor agonist · 12
• Cannabinoid · 11
• Dopamine precursor with peripheral decarboxylase inhibitor · 11
• Sympathomimetic amine; central nervous system stimulant · 10

Major diseases in this area

• alzheimers disease
• multiple sclerosis
• parkinsons disease

Subscribe

Get neurology approvals + PDUFA dates in your RSS reader:

• Neurology RSS feed · Atom · JSON

Other therapeutic areas